Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 255-260

  Kim, Kyoung Soo ^a   Choi, Hyun Mi ^a   Ji, Hye In ^a   Song, Ran ^b   Yang, Hyung In ^b   Lee, Soo Kon ^c   Yoo, Myung Chul ^a   Park, Yong Beom ^c  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Adipokine; Adiponectin; Disease modifying antirheumatic drugs; Rheumatoid arthritis; Tumor necrosis factor blocker

Indexed keywords

ADIPOKINES; ADIPONECTIN; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893828861     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1764     Document Type: Article

References (25)

1. Trayhurn P and Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92: 347-355, 2004.
2. Wozniak SE, Gee LL, Wachtel MS and Frezza EE: Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 54: 1847-1856, 2009.
3. Kontny E, Plebanczyk M, Lisowska B, et al.: Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis 71: 262-267, 2012.
4. Gomez R, Conde J, Scotece M, et al.: What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7: 528-536, 2011.
5. Neumann E, Frommer KW, Vasile M and Müller-Ladner U: Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 63: 1159-1169, 2011.
6. Ehling A, Schaffler A, Herfarth H, et al.: The potential of adiponectin in driving arthritis. J Immunol 176: 4468-4478, 2006.
7. Kitahara K, Kusunoki N, Kakiuchi T, Suguro T and Kawai S: Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 378: 218-223, 2009.
8. Stofkova A: Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 43: 157-168, 2009.
9. Luk T, Malam Z and Marshall JC: Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83: 804-816, 2008.
10. Brentano F, Schorr O, Ospelt C, et al.: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56: 2829-2839, 2007.
11. Bokarewa M, Nagaev I, Dahlberg L, Smith U and Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 174: 5789-5795, 2005.
12. Arnett FC, Edworthy SM, Bloch DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.
13. Inoue E, Yamanaka H, Hara M, Tomatsu T and Kamatani N: Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 66: 407-409, 2007.
14. Fries JF, Spitz P, Kraines RG and Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 23: 137-145, 1980.
15. Felson DT, Anderson JJ, Boers M, et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727-735, 1995.
16. Cansu B, Cansu DU, Kaşifoģlu T, Gülbas Z and Korkmaz C: Disease-modifying antirheumatic drugs increase serum adiponectin levels in patients with rheumatoid arthritis. J Clin Rheumatol 17: 14-17, 2011.
17. Lewicki M, Kotyla P and Kucharz E: Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin Rheumatol 27: 1337-1338, 2008.
18. Komai N, Morita Y, Sakuta T, Kuwabara A and Kashihara N: Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17: 385-390, 2007.
19. Popa C, Netea MG, de Graaf J, et al.: Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 36: 724-730, 2009.
20. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, et al.: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 28: 56-62, 2010.
21. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26: 311-316, 2008.
22. Popa C, Netea MG, Radstake TR, et al.: Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64: 1195-1198, 2005.
23. Presle N, Pottie P, Dumond H, et al.: Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 14: 690-695, 2006.
24. Senolt L, Pavelka K, Housa D and Haluzik M: Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 35: 247-252, 2006
25. Neumeier M, Weigert J, Schäffler A, et al.: Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 79: 803-808, 2006.